Actively Recruiting
Phase 12a Study Evaluating Safety of VOY-101 Injection in Patients 60 Years and Older With Advanced Non-Neovascular Age-Related Macular Degeneration
Led by Perceive Biotherapeutics, Inc. · Updated on 2025-10-15
60
Participants Needed
11
Research Sites
39 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety of a new treatment called VOY-101 for people aged 60 and older who have advanced non-neovascular age-related macular degeneration AMD, including geographic atrophy. This Phase 12a study focuses on understanding how well this treatment works to protect and improve retinal health in this condition. The study is open-label and conducted at multiple centers. Participants will receive a single injection of VOY-101 into one eye. The study includes escalating dose groups to find the safest and most effective dose. There is also a control group where the fellow eye receives no intervention. Treatment effects will be monitored over time, including longer-term follow-up to assess safety and vision changes. During the study, participants will have regular eye exams, imaging tests, and vision function assessments at scheduled visits up to 96 weeks. Researchers will measure retinal structural health and vision changes, and monitor for any development of neovascular AMD or side effects related to VOY-101. Participants need to be able to complete vision testing and attend all study visits.
CONDITIONS
Brief Title
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
Research Team
A
Anne Fung, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
